iRhythm Technologies Inc

IRTC remains in a persistent Stage 4 decline with clear lower highs and lower lows under declining EMAs and DMAs. The medium-term tradable side is bearish, confirmed by persistent rejection at the 9- and 21-EMAs. In the short term, price action shows recent rejection at these EMAs, creating a favorable opportunity to sell now into the EMA resistance zone.

• ↑Q1 2026 revenue $199.4M (+25.7% YoY) driven by new account growth
• ↑FY26 revenue outlook upped to $875–885M on strong Zio demand
• ↓Ongoing FDA warning-letter compliance may delay product rollouts